Immunohistochemical Analysis of Expressions of RB1,CDK4,HSP90,cPLA2G4A,and CHMP2B Is Helpful in Distinction between Myxofibrosarcoma and Myxoid Liposarcoma
Restricted accessResearch articleFirst published online October, 2014
Immunohistochemical Analysis of Expressions of RB1,CDK4,HSP90,cPLA2G4A,and CHMP2B Is Helpful in Distinction between Myxofibrosarcoma and Myxoid Liposarcoma
The role and diagnostic efficacy of gene and protein products RB1, CDK4, CHMP2B, HSP90, and cPLA2G4A, all previously shown to be involved in tumor genesis and cell proliferation, were examined by immunohistochemical techniques in 32 cases of myxofibrosarcomas and 29 myxoid liposarcomas (all diagnosis had been confirmed by fluorescence in situ hybridization). HSP90 demonstrated strong nuclear and cytoplasmic positivity in all myxoid liposarcoma cases, while only 4 myxofibrosarcomas showed scattered HSP90 positivity. All but 4 cases of myxofibrosarcoma displayed strong positivity for cPLA2G4A, while only 2 myxoid liposarcoma cases were cPLA2G4A positive and both were CHMP2B negative. Overexpression of both cPLA2G4A and CHMP2B also suggested higher tumor grade. In conclusion, HSP90 and cPLA2G4A immunohistochemical stains are useful markers to distinguish myxofibrosarcoma from myxoid liposarcoma.
FletcherCDMHogendoormPCWMertensFBridgeJ, eds. WHO Classification of Tumors of Soft Tissue and Bone. Lyon, France: IARC Press; 2013.
2.
MandahlNHeimSKristofferssonU. Telomeric association in a malignant fibrous histiocytoma. Hum Genet. 1985;71:321-324.
3.
MolenaarWMDeJongBBuistJ. Chromosomal analysis and the classification of soft tissue sarcomas. Lab Invest. 1989;60:266-274.
4.
OrndalCRydholmAWillenHMitelmanFMandahlN. Cytogenetic intratumor heterogeneity in soft tissue tumors. Cancer Genet Cytogenet. 1994;78:127-137.
5.
NishioJIwasakiHNabeshimaKNaitoM. Cytogenetics and molecular genetics of myxoid soft-tissue sarcomas. Genet Res Int. 2011;2011:497148.
6.
MentzelTCalonjeEWaddenC. Myxofibrosarcoma. Clinicopathologic analysis of 75 cases with emphasis on the low-grade variant. Am J Surg Pathol. 1996;20:391-405.
7.
MerckCAngervallLKindblomLGOdenA. Myxofibrosarcoma. A malignant soft tissue tumor of fibroblastic-histiocytic origin. A clinicopathologic and prognostic study of 110 cases using multivariate analysis. Acta Pathol Microbiol Immunol Scand Suppl. 1983;282:1-40.
8.
WeissSWEnzingerFM. Myxoid variant of malignant fibrous histiocytoma. Cancer. 1977;39:1672-1685.
9.
DewanVDarbyshireASumathiVJeysLGrimerR. Prognostic and survival factors in myxofibrosarcomas. Sarcoma. 2012;2012:830879.
10.
FletcherCDMUnniKKMertensF eds. WHO Classification of Tumors. Pathology and Genetics Tumor of Soft Tissue and Bone. Lyon, France: IARC Press; 2002.
11.
FolpeALInwardsCY, eds. Bone and Soft Tissue Pathology. Philadelphia, PA: Saunders Elsevier; 2010.
12.
BolandJMColbyTVFolpeAL. Liposarcomas of the mediastinum and thorax: a clinicopathologic and molecular cytogenetic study of 24 cases, emphasizing unusual and diverse histologic features. Am J Surg Pathol. 2012;36:1395-1403.
13.
AmanPRonDMandahlN. Rearrangement of the transcription factor gene CHOP in myxoid liposarcomas with t(12;16)(q13;p11). Genes Chromosomes Cancer. 1992;5:278-285.
14.
CrozatAAmanPMandahlNRonD. Fusion of CHOP to a novel RNA-binding protein in human myxoid liposarcoma. Nature. 1993;363:640-644.
15.
Perez-LosadaJPintadoBGutierrez-AdanA. The chimeric FUS/TLS-CHOP fusion protein specifically induces liposarcomas in transgenic mice. Oncogene. 2000;19:2413-2422.
16.
RabbittsTHForsterALarsonRNathanP. Fusion of the dominant negative transcription regulator CHOP with a novel gene FUS by translocation t(12;16) in malignant liposarcoma. Nat Genet. 1993;4:175-180.
17.
KilpatrickSEDoyonJChoongPFSimFHNascimentoAG. The clinicopathologic spectrum of myxoid and round cell liposarcoma. A study of 95 cases. Cancer. 1996;77:1450-1458.
18.
HaniballJSumathiVPKindblomLG. Prognostic factors and metastatic patterns in primary myxoid/round-cell liposarcoma. Sarcoma. 2011;2011:538085.
19.
AntonescuCRTschernyavskySJDecusearaR. Prognostic impact of P53 status, TLS-CHOP fusion transcript structure, and histological grade in myxoid liposarcoma: a molecular and clinicopathologic study of 82 cases. Clin Cancer Res. 2001;7:3977-3987.
SmithTAEasleyKAGoldblumJR. Myxoid/round cell liposarcoma of the extremities. A clinicopathologic study of 29 cases with particular attention to extent of round cell liposarcoma. Am J Surg Pathol. 1996;20:171-180.
22.
Dei TosAPPiccininSDoglioniC. Molecular aberrations of the G1-S checkpoint in myxoid and round cell liposarcoma. Am J Pathol. 1997;151:1531-1539.
23.
Dei TosAPMaestroRDoglioniC. Tumor suppressor genes and related molecules in leiomyosarcoma. Am J Pathol. 1996;148:1037-1045.
24.
KarpehMSBrennanMFCanceWG. Altered patterns of retinoblastoma gene product expression in adult soft-tissue sarcomas. Br J Cancer. 1995;72:986-991.
25.
CohenJAGeradtsJ. Loss of RB and MTS1/CDKN2 (p16) expression in human sarcomas. Hum Pathol. 1997;28:893-898.
26.
SabahMCumminsRLeaderMKayE. Aberrant expression of the Rb pathway proteins in soft tissue sarcomas. Appl Immunohistochem Mol Morphol. 2006;14:397-403.
27.
Dei TosAPDoglioniCPiccininS. Molecular abnormalities of the p53 pathway in dedifferentiated liposarcoma. J Pathol. 1997;181:8-13.
28.
KhatibZAMatsushimeHValentineMShapiroDNSherrCJLookAT. Coamplification of the CDK4 gene with MDM2 and GLI in human sarcomas. Cancer Res. 1993;53:5535-5541.
29.
YaoJPollockRELangA. Infrequent mutation of the p16/MTS1 gene and overexpression of cyclin-dependent kinase 4 in human primary soft-tissue sarcoma. Clin Cancer Res. 1998;4:1065-1070.
30.
Helias-RodzewiczZPerotGChibonF. YAP1 and VGLL3, encoding two cofactors of TEAD transcription factors, are amplified and overexpressed in a subset of soft tissue sarcomas. Genes Chromosomes Cancer. 2010;49:1161-1171.
31.
BaumhoerDGlatzKSchultenHJ. Myxoinflammatory fibroblastic sarcoma: investigations by comparative genomic hybridization of two cases and review of the literature. Virchows Arch. 2007;451:923-928.
32.
HallorKHSciotRStaafJ. Two genetic pathways, t(1;10) and amplification of 3p11-12, in myxoinflammatory fibroblastic sarcoma, haemosiderotic fibrolipomatous tumour, and morphologically similar lesions. J Pathol. 2009;217:716-727.
33.
KangGHLeeEJJangKT. Expression of HSP90 in gastrointestinal stromal tumours and mesenchymal tumours. Histopathology. 2010;56:694-701.
34.
DicksonMAOkunoSHKeohanML. Phase II study of the HSP90-inhibitor BIIB021 in gastrointestinal stromal tumors. Ann Oncol. 2013;24:252-257.
35.
MartinsASOrdonezJLGarcia-SanchezA. A pivotal role for heat shock protein 90 in Ewing sarcoma resistance to anti-insulin-like growth factor 1 receptor treatment: in vitro and in vivo study. Cancer Res. 2008;68:6260-6270.
36.
RaoUNHoodBLJones-LaughnerJMSunMConradsTP. Distinct profiles of oxidative stress-related and matrix proteins in adult bone and soft tissue osteosarcoma and desmoid tumors: a proteomics study. Hum Pathol. 2013;44:725-733.
37.
MoonABacchiniPBertoniF. Expression of heat shock proteins in osteosarcomas. Pathology. 2010;42:421-425.
38.
BuhmeidaABendardafRHilskaM. PLA2 (group IIA phospholipase A2) as a prognostic determinant in stage II colorectal carcinoma. Ann Oncol. 2009;20:1230-1235.
39.
SvedPScottKFMcLeodD. Oncogenic action of secreted phospholipase A2 in prostate cancer. Cancer Res. 2004;64:6934-6940.
40.
YamashitaSYamashitaJOgawaM. Overexpression of group II phospholipase A2 in human breast cancer tissues is closely associated with their malignant potency. Br J Cancer. 1994;69:1166-1170.
IshibashiHSuzukiTSuzukiS. Sex steroid hormone receptors in human thymoma. J Clin Endocrinol Metab. 2003;88:2309-2317.
43.
NishioJ. Contributions of cytogenetics and molecular cytogenetics to the diagnosis of adipocytic tumors. J Biomed Biotechnol. 2011;2011:524067.
44.
SandbergAA. Updates on the cytogenetics and molecular genetics of bone and soft tissue tumors: liposarcoma. Cancer Genet Cytogenet. 2004;155:1-24.
45.
ConyersRYoungSThomasDM. Liposarcoma: molecular genetics and therapeutics. Sarcoma. 2011;2011:483154.
46.
GuillouLBenhattarJGenglerC. Translocation-positive low-grade fibromyxoid sarcoma: clinicopathologic and molecular analysis of a series expanding the morphologic spectrum and suggesting potential relationship to sclerosing epithelioid fibrosarcoma: a study from the French Sarcoma Group. Am J Surg Pathol. 2007;31:1387-1402.
47.
StorlazziCTMertensFNascimentoA. Fusion of the FUS and BBF2H7 genes in low grade fibromyxoid sarcoma. Hum Mol Genet. 2003;12:2349-2358.
48.
PanagopoulosIStorlazziCTFletcherCD. The chimeric FUS/CREB3l2 gene is specific for low-grade fibromyxoid sarcoma. Genes Chromosomes Cancer. 2004;40:218-228.
49.
MertensFFletcherCDAntonescuCR. Clinicopathologic and molecular genetic characterization of low-grade fibromyxoid sarcoma, and cloning of a novel FUS/CREB3L1 fusion gene. Lab Invest. 2005;85:408-415.
50.
ElcoCPMarino-EnriquezAAbrahamJADal CinPHornickJL. Hybrid myxoinflammatory fibroblastic sarcoma/hemosiderotic fibrolipomatous tumor: report of a case providing further evidence for a pathogenetic link. Am J Surg Pathol. 2010;34:1723-1727.
51.
AntonescuCRZhangLNielsenGPRosenbergAEDal CinPFletcherCD. Consistent t(1;10) with rearrangements of TGFBR3 and MGEA5 in both myxoinflammatory fibroblastic sarcoma and hemosiderotic fibrolipomatous tumor. Genes Chromosomes Cancer. 2011;50:757-764.
SjogrenHMeis-KindblomJMOrndalC. Studies on the molecular pathogenesis of extraskeletal myxoid chondrosarcoma-cytogenetic, molecular genetic, and cDNA microarray analyses. Am J Pathol. 2003;162:781-792.
54.
PanagopoulosIMertensFIsakssonM. Molecular genetic characterization of the EWS/CHN and RBP56/CHN fusion genes in extraskeletal myxoid chondrosarcoma. Genes Chromosomes Cancer. 2002;35:340-352.
55.
HarrisMCoyneJTariqM. Extraskeletal myxoid chondrosarcoma with neuroendocrine differentiation: a pathologic, cytogenetic, and molecular study of a case with a novel translocation t(9;17)(q22;q11.2). Am J Surg Pathol. 2000;24:1020-1026.
56.
AlaggioRCoffinCMWeissSW. Liposarcomas in young patients: a study of 82 cases occurring in patients younger than 22 years of age. Am J Surg Pathol. 2009;33:645-658.
57.
HamelPAPhillipsRAMuncasterMGallieBL. Speculations on the roles of RB1 in tissue-specific differentiation, tumor initiation, and tumor progression. FASEB J. 1993;7:846-854.
58.
StrattonMRCampbellPJFutrealPA. The cancer genome. Nature. 2009;458:719-724.
59.
WoodLDParsonsDWJonesS. The genomic landscapes of human breast and colorectal cancers. Science. 2007;318:1108-1113.
60.
BinhMBSastre-GarauXGuillouL. MDM2 and CDK4 immunostainings are useful adjuncts in diagnosing well-differentiated and dedifferentiated liposarcoma subtypes: a comparative analysis of 559 soft tissue neoplasms with genetic data. Am J Surg Pathol. 2005;29:1340-1347.
61.
WuC. Heat shock transcription factors: structure and regulation. Annu Rev Cell Dev Biol. 1995;11:441-469.
62.
De MaioA. Heat shock proteins: facts, thoughts, and dreams. Shock. 1999;11:1-12.
GrenertJPSullivanWPFaddenP. The amino-terminal domain of heat shock protein 90 (hsp90) that binds geldanamycin is an ATP/ADP switch domain that regulates hsp90 conformation. J Biol Chem. 1997;272:23843-23850.
65.
WegeleHMullerLBuchnerJ. Hsp70 and Hsp90—a relay team for protein folding. Rev Physiol Biochem Pharmacol. 2004;151:1-44.
66.
ImaiJMaruyaMYashirodaHYaharaITanakaK. The molecular chaperone Hsp90 plays a role in the assembly and maintenance of the 26S proteasome. EMBO J. 2003;22:3557-3567.
67.
BuchnerJ. Hsp90 & Co —a holding for folding. Trends Biochem Sci. 1999;24:136-141.
68.
GazittYKolaparthiVMoncadaKThomasCFreemanJ. Targeted therapy of human osteosarcoma with 17AAG or rapamycin: characterization of induced apoptosis and inhibition of mTOR and Akt/MAPK/Wnt pathways. Int J Oncol. 2009;34:551-561.
